Revised SPC: Avastin (bevacizumab) 25mg/ml concentrate for solution for infusion -

Revised SPC: Avastin (bevacizumab) 25mg/ml concentrate for solution for infusion
Information type: Drug prescribing
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Cancers
Summary
SPC updated with new indication: use in combination with paclitaxel and cisplatin or paclitaxel and topotecan for treatment of persistent, recurrent, or metastatic carcinoma of the cervix in patients who cannot receive platinum therapy.
UKMi comment
Bevacizumab for the first line treatment of recurrent or metastatic cervical cancer in combination with chemotherapy is on the National Cancer Drugs Fund List of approved uses.
Related links: